213 results
Page 5 of 11
8-K
EX-99.1
amk d0khx17
9 Nov 10
Results of Operations and Financial Condition
12:00am
CORRESP
nprqy1f fp5fdb
8 Nov 10
Correspondence with SEC
12:00am
8-K
EX-99.1
480 t4ytg8sie2mx
21 Oct 10
Discovery Labs Appoints W. Thomas Amick as Chief Executive Officer
12:00am
8-K
vkp6dmug592l84
21 Oct 10
Discovery Labs Appoints W. Thomas Amick as Chief Executive Officer
12:00am
424B5
o2gh zpy45bepfdb
13 Oct 10
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
0op bvwzd6xp0tbm7fr
13 Oct 10
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
oompzrzmha
4 Aug 10
Discovery Labs Provides Business Update and Reports Second Quarter 2010 Financial Results
12:00am
424B5
zxfz 6zt8unb4n9
18 Jun 10
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
cnb8tqhj
17 Jun 10
Discovery Labs Prices $10.0 Million Public Offering of
12:00am
424B5
ea29a5vhnc
16 Jun 10
Prospectus supplement for primary offering
12:00am
424B3
a9mnmflv
15 Jun 10
Prospectus supplement
12:00am
8-K
EX-99.1
jf78 mft8c1sj
14 Jun 10
Discovery Labs Secures $35 Million Committed Equity Financing Facility
12:00am
8-K
EX-99.1
mb7uvogtp4v
9 Jun 10
Discovery Labs Receives FDA Guidance Regarding Preclinical Program to
12:00am
8-K
EX-99.1
ywa79
9 Jun 10
Discovery Labs Reports Preliminary Results from Phase 2 Clinical Trial of Surfaxin in Pediatric Acute Respiratory Failure
12:00am
8-K
EX-99.1
purf ti93
4 Jun 10
Discovery Labs Announces Listing Transfer to NASDAQ Capital Market
12:00am
8-K
EX-99.1
ru4lkc9 c1mb
21 May 10
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin® Approval
12:00am